Novo's Wegovy Faces Market Challenges Amid Zepbound Growth

Novo Nordisk's Wegovy reduced heart attack, stroke, or death risk by 57% compared to Mounjaro and Zepbound in overweight and obese patients with cardiovascular disease but not diabetes.
Wegovy users had 29% lower heart risk and death rate than tirzepatide users, regardless of treatment gaps.
Novo lost U.S. market share to Zepbound since becoming Europe's most valuable company last year.

Market | Drugs | Study

United States | Europe

2 weeks ago